JP2014511847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511847A5 JP2014511847A5 JP2014502642A JP2014502642A JP2014511847A5 JP 2014511847 A5 JP2014511847 A5 JP 2014511847A5 JP 2014502642 A JP2014502642 A JP 2014502642A JP 2014502642 A JP2014502642 A JP 2014502642A JP 2014511847 A5 JP2014511847 A5 JP 2014511847A5
- Authority
- JP
- Japan
- Prior art keywords
- synthetic nanocarrier
- osmotic
- dosage form
- release barrier
- mediated release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467595P | 2011-03-25 | 2011-03-25 | |
| US61/467,595 | 2011-03-25 | ||
| PCT/US2012/030314 WO2012135010A2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231391A Division JP2018076331A (ja) | 2011-03-25 | 2017-12-01 | 浸透圧媒介性放出合成ナノ担体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511847A JP2014511847A (ja) | 2014-05-19 |
| JP2014511847A5 true JP2014511847A5 (https=) | 2015-05-14 |
| JP6320912B2 JP6320912B2 (ja) | 2018-05-09 |
Family
ID=46877545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502642A Active JP6320912B2 (ja) | 2011-03-25 | 2012-03-23 | 浸透圧媒介性放出合成ナノ担体 |
| JP2017231391A Pending JP2018076331A (ja) | 2011-03-25 | 2017-12-01 | 浸透圧媒介性放出合成ナノ担体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231391A Pending JP2018076331A (ja) | 2011-03-25 | 2017-12-01 | 浸透圧媒介性放出合成ナノ担体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20120244222A1 (https=) |
| EP (1) | EP2694040A4 (https=) |
| JP (2) | JP6320912B2 (https=) |
| KR (1) | KR20140022025A (https=) |
| CN (1) | CN103458879A (https=) |
| AU (2) | AU2012236937B2 (https=) |
| BR (1) | BR112013024655A2 (https=) |
| CA (1) | CA2830948A1 (https=) |
| EA (1) | EA201391392A1 (https=) |
| MX (1) | MX366228B (https=) |
| WO (1) | WO2012135010A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0639059B2 (ja) | 1985-11-08 | 1994-05-25 | キヤノン株式会社 | 光導電部材用基体の製造装置 |
| JP2706993B2 (ja) | 1988-11-25 | 1998-01-28 | キヤノン株式会社 | 光導電部材用基体の製造装置 |
| CA2762653A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| CN107617110A (zh) * | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | 诱导t细胞辅助的组合物 |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| HUE052599T2 (hu) | 2013-05-03 | 2021-05-28 | Selecta Biosciences Inc | CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CA3236835A1 (en) | 2013-11-22 | 2015-05-28 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| AU2015311704B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| KR101646181B1 (ko) | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물 |
| RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| AR108280A1 (es) * | 2016-05-05 | 2018-08-08 | Acraf | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| EP3551230A1 (en) | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CA3075205A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
| WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
| US12357582B2 (en) * | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
| EP3775211B1 (en) | 2018-04-12 | 2023-04-05 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| CN114207440A (zh) | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| AU2020355000A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| CN116096886A (zh) | 2020-03-11 | 2023-05-09 | 欧米茄治疗公司 | 用于调节叉头框p3(foxp3)基因表达的组合物和方法 |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4314292A1 (en) | 2021-03-26 | 2024-02-07 | MiNA Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5186941A (en) * | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US4855132A (en) * | 1986-02-25 | 1989-08-08 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| EP1126826B3 (en) * | 1998-11-02 | 2019-05-15 | Alkermes Pharma Ireland Limited | Multiparticulate modified release composition of methylphenidate |
| GB0009735D0 (en) * | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
| CA2313659A1 (en) * | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
| MXPA03002640A (es) * | 2000-09-28 | 2003-06-19 | Chiron Corp | Microparticulas para la distribucion de acidos nucleicos heterologos. |
| US20030215394A1 (en) * | 2002-05-17 | 2003-11-20 | Short Robert E. | Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream |
| JP4038585B2 (ja) * | 2002-06-03 | 2008-01-30 | 宮崎県 | 固体脂マイクロカプセルおよびその製造方法 |
| US7060299B2 (en) * | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| JP2009507049A (ja) * | 2005-09-09 | 2009-02-19 | 北京徳科瑞医薬科技有限公司 | リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤 |
| WO2008051245A2 (en) * | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
| EP2231264A1 (en) * | 2007-12-05 | 2010-09-29 | Eyegate Pharma S.A.S. | Methods for delivering sirna via iontophoresis |
| EP3067048B1 (en) * | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| FR2935901A1 (fr) * | 2008-09-16 | 2010-03-19 | Inst Curie | Polymersome asymetrique stimulable. |
| CA2762653A1 (en) * | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
-
2012
- 2012-03-23 CA CA2830948A patent/CA2830948A1/en not_active Abandoned
- 2012-03-23 EA EA201391392A patent/EA201391392A1/ru unknown
- 2012-03-23 EP EP12764409.4A patent/EP2694040A4/en not_active Withdrawn
- 2012-03-23 BR BR112013024655A patent/BR112013024655A2/pt not_active Application Discontinuation
- 2012-03-23 KR KR1020137027777A patent/KR20140022025A/ko not_active Ceased
- 2012-03-23 CN CN2012800146549A patent/CN103458879A/zh active Pending
- 2012-03-23 JP JP2014502642A patent/JP6320912B2/ja active Active
- 2012-03-23 WO PCT/US2012/030314 patent/WO2012135010A2/en not_active Ceased
- 2012-03-23 AU AU2012236937A patent/AU2012236937B2/en active Active
- 2012-03-23 US US13/428,340 patent/US20120244222A1/en not_active Abandoned
- 2012-03-23 MX MX2013010972A patent/MX366228B/es active IP Right Grant
-
2017
- 2017-05-17 AU AU2017203307A patent/AU2017203307A1/en not_active Abandoned
- 2017-12-01 JP JP2017231391A patent/JP2018076331A/ja active Pending
-
2022
- 2022-07-28 US US17/815,877 patent/US20230139671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511847A5 (https=) | ||
| JP2018076331A5 (https=) | ||
| AR081679A1 (es) | Metodos y composiciones para la administracion intratecal de heparan n-sulfatasa, envase | |
| AR080427A1 (es) | Formulacion liquida para un conjugado de accion prolongada del g-csf | |
| JP2009540001A5 (https=) | ||
| JP2014514275A5 (https=) | ||
| JP2015134763A5 (https=) | ||
| ECSP12011722A (es) | Formulaciones farmacéuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| JP2014139229A5 (https=) | ||
| US20160310412A1 (en) | Microneedle | |
| JP2017128569A5 (https=) | ||
| KR20150127206A (ko) | 나노입자-기재 조성물 | |
| JP2014040441A5 (https=) | ||
| JP2015536942A5 (https=) | ||
| RU2011127913A (ru) | Составы, содержащие антитела | |
| JP2013079270A5 (https=) | ||
| JP2005526084A5 (https=) | ||
| JP2013531679A5 (https=) | ||
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| KR20140022025A (ko) | 삼투적 매개 방출 합성 나노담체 | |
| CY1114590T1 (el) | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα | |
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| AR070824A1 (es) | Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas | |
| RU2021108337A (ru) | Состав для введения рнк |